MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-21-2026
Country |
 China |
IPO year |
2018 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
5.45 M |
Market Cap[1] |
$ 5.07 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Verastem
VSTM
|
$ 5.04 | -4.73 % | $ 349 M | Nasdaq Global Market |  USA |
 |
VistaGen Therapeutics
VTGN
|
$ 0.57 | -5.87 % | $ 17.6 M | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 12.41 | -11.1 % | $ 1.88 B | Nasdaq Global Select Market,SPB | USA |
 |
Xenon Pharmaceuticals
XENE
|
$ 54.48 | -1.89 % | $ 4.24 B | Nasdaq Global Select Market |  Canada |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
ChemoCentryx
CCXI
|
- | - | $ 3.74 B | Nasdaq Global Select Market,SPB | USA |
 |
Enochian Biosciences
ENOB
|
- | - | $ 40.5 M | Nasdaq Capital Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Summit Therapeutics
SMMT
|
$ 16.58 | -3.94 % | $ 12.4 B | Nasdaq Global Select Market | Britain |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 317.36 | -3.29 % | $ 41.6 B | Nasdaq Global Select Market,SPB | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.29 | -3.6 % | $ 822 M | Nasdaq Global Select Market | Canada |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
 |
Fusion Pharmaceuticals
FUSN
|
- | - | $ 1.41 B | Nasdaq Global Select Market | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 19.01 | -2.66 % | $ 889 M | Nasdaq Global Select Market | USA |
 |
Gritstone Oncology
GRTS
|
- | 0.42 % | $ 213 M | Nasdaq Global Select Market | USA |
 |
Завод ДИОД
DIOD
|
- | - | - | MOEX,SPB | Russia |
 |
Фармсинтез
LIFE
|
- | - | - | MOEX | Russia |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 20.75 | -3.35 % | $ 3.44 B | Nasdaq Global Select Market,SPB | USA |
 |
Aligos Therapeutics
ALGS
|
$ 6.66 | -5.4 % | $ 65.8 M | Nasdaq Global Select Market | USA |
 |
Teligent, Inc.
TLGT
|
- | -13.85 % | $ 16.1 M | Nasdaq Global Select Market | USA |
 |
Viela Bio, Inc.
VIE
|
- | - | $ 2.91 B | Nasdaq Global Select Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Alkermes plc
ALKS
|
$ 29.39 | -1.77 % | $ 4.84 B | Nasdaq Global Select Market |  Irlanda |
 |
Cabaletta Bio
CABA
|
$ 2.68 | -4.96 % | $ 269 M | Nasdaq Global Select Market | USA |
 |
AbbVie
ABBV
|
$ 209.4 | -0.81 % | $ 370 B | NYSE,SPB | USA |
 |
AbCellera Biologics
ABCL
|
$ 3.27 | -2.39 % | $ 977 M | Nasdaq Global Select Market | Canada |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.